Abstract: The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate a series of disease symptoms associated with Alzheimer's-type dementia in dementia model animals, and thus can be effectively used as a pharmaceutical composition capable of preventing or treating nervous system diseases comprising neurodegenerative diseases and mTORopathy.

Abstract: The composition comprising athyriol or a pharmaceutically acceptable salt thereof as an active ingredient, according to the present application, does not inhibit mTORC1 activity but selectively inhibits mTORC2 in an effective concentration and thus may be effectively used for preventing or treating mTORopathies, particularly autism spectrum disorder and neurodevelopmental disorders, which are caused by hyperactivated mTORC2.

Abstract: The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate a series of disease symptoms associated with Alzheimer's-type dementia in dementia model animals, and thus can be effectively used as a pharmaceutical composition capable of preventing or treating nervous system diseases comprising neurodegenerative diseases and mTORopathy.

Abstract: The present invention relates to a composition for preventing or treating neuropsychologic diseases, the composition including placental growth factor (PLGF), or a peptide derived therefrom or a fragment thereof. The administration of the PLGF according to the present invention promotes the differentiation of GABAergic (?-aminobutyric acid, GABA) nerve cells in a memory impairment and autism model to induce nerve regeneration, to enhance memory ability and to ameliorate decline in social cognition, sociability and social sexual preference, whereby a composition for preventing or treating neuropsychologic diseases such as autism, ADHD, mental retardation disorder, and developmental disorder can be provided.

Abstract: The present invention relates to a composition for preventing or treating neuropsychologic diseases, the composition comprising a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF), a peptide derived therefrom or a fragment thereof. The administration of the MANF according to the present invention promotes the differentiation of cholinergic and/or GABAergic (?-aminobutyric acid) nerve cells in models of memory impairment and autism to induce nerve regeneration, exhibits the effects of enhancing memory and ameliorating emotional anxiety, and ameliorates social cognition, sociability and decline in social sexual preference, whereby a composition for preventing or treating neuropsychologic diseases such as autism, ADHD, mental retardation disorder, and developmental disorder can be provided.